Hepion Pharmaceuticals

Hepion Pharmaceuticals, listed on Nasdaq under the ticker HEPA, is a clinical-stage biopharmaceutical company specializing in the development of targeted therapies for liver diseases, particularly those arising from non-alcoholic steatohepatitis (NASH) and chronic hepatitis virus infections (HBV, HCV, HDV). The company's lead drug candidate, CRV431, has shown promise in reducing liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH.

Hepion leverages advanced technologies such as Artificial Intelligence (AI), Machine Learning (ML), and Deep Learning to decode diseases, develop targeted therapies, and identify patients who are most likely to respond to their treatments. This tech-driven approach aims to enhance the precision and efficacy of their drug development process.

The company primarily serves the healthcare market, focusing on patients suffering from chronic liver diseases. Its business model revolves around the research, development, and commercialization of its drug candidates. Revenue is generated through public offerings, partnerships, and eventually, the sale of approved therapies.

Keywords: liver disease, NASH, hepatitis, AI, ML, deep learning, CRV431, fibrosis, hepatocellular carcinoma, biopharmaceutical.